PR

ProGen, Co,, LTD.

Develops protein-based immunotherapies for metabolic diseases, immune disorders, and cancer.

296160 | KO

Overview

Corporate Details

ISIN(s):
KR7296160005
LEI:
Country:
South Korea
Address:
서울특별시 강서구 마곡중앙로 172, 6층, 7층, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ProGen is a clinical-stage biotechnology company focused on the research and development of innovative therapeutics. The company specializes in creating protein-based immunotherapies through its proprietary Neo Tri-ImmunoGlobulin (NTIG) platform, a next-generation technology for developing multi-specific fusion proteins and antibody treatments. ProGen's pipeline primarily targets metabolic diseases, immune disorders, and cancer. The company's business model is centered on platform-based drug discovery and pursuing global partnerships for late-stage clinical development and commercialization of its long-acting biologics.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-05 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 65.8 KB
2025-08-18 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 24.2 KB
2025-08-18 00:00
Regulatory News Service
지정자문인선임계약의변경
Korean 5.1 KB
2025-07-15 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-07-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 99.0 KB
2025-07-07 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 122.5 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-06-11 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 16.7 KB
2025-06-11 00:00
Remuneration Information
[기재정정]주식매수선택권부여에관한신고
Korean 42.2 KB
2025-06-11 00:00
Share Issue/Capital Change
[기재정정]주식매수선택권부여에관한신고
Korean 25.8 KB
2025-05-28 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 43.5 KB
2025-05-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 123.5 KB
2025-05-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-05-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB

Automate Your Workflow. Get a real-time feed of all ProGen, Co,, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ProGen, Co,, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ProGen, Co,, LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alteogen Inc. Logo
Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.
South Korea
196170
ALTERITY THERAPEUTICS LTD Logo
Developing therapies for Parkinsonian disorders and MSA by inhibiting protein aggregation.
United States of America
ATHE
Alto Neuroscience, Inc. Logo
Developing precision medicines for depression and schizophrenia using a brain biomarker platform.
United States of America
ANRO
ALUMIS INC. Logo
Develops targeted oral therapies for immune-mediated diseases using precision immunology.
United States of America
ALMS
Alvotech Holdings S.A Logo
Develops and manufactures affordable biosimilar medicines for global patient access.
Luxembourg
ALVO
ALX ONCOLOGY HOLDINGS INC Logo
Clinical-stage firm developing CD47 inhibitors for hematologic and solid tumors.
United States of America
ALXO
Alzamend Neuro, Inc. Logo
Developing lithium & vaccine therapies for neurodegenerative & psychiatric disorders.
United States of America
ALZN
Alzinova AB Logo
Developing targeted immunotherapies, including a vaccine, for Alzheimer's disease.
Sweden
ALZ
AMARIN CORP PLC\UK Logo
Develops prescription therapies like Vascepa® to reduce cardiovascular risk for patients.
United States of America
AMRN
AMGEN INC Logo
Biotech pioneer developing innovative human therapeutics for the world's toughest diseases.
United States of America
AMGN

Talk to a Data Expert

Have a question? We'll get back to you promptly.